Next Article in Journal
Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement
Next Article in Special Issue
The “Little Iron Waltz”: The Ternary Response of Paracoccidioides spp. to Iron Deprivation
Previous Article in Journal
Insights into the Multi-Azole Resistance Profile in Candida haemulonii Species Complex
Previous Article in Special Issue
Phylogenetic Species of Paracoccidioides spp. Isolated from Clinical and Environmental Samples in a Hyperendemic Area of Paracoccidioidomycosis in Southeastern Brazil
Open AccessReview

The Therapy of Pulmonary Fibrosis in Paracoccidioidomycosis: What Are the New Experimental Approaches?

Basic and Applied Microbiology Research Group (MICROBA), School of Microbiology, Universidad de Antioquia, 050031 Medellin, Colombia
J. Fungi 2020, 6(4), 217; https://doi.org/10.3390/jof6040217
Received: 18 September 2020 / Revised: 6 October 2020 / Accepted: 9 October 2020 / Published: 11 October 2020
(This article belongs to the Special Issue Paracoccidioides and Paracoccidioidomycosis)
Pulmonary fibrosis (PF) is considered the most important sequela developed in patients suffering from the chronic form of paracoccidioidomycosis (PCM), which leads to the loss of respiratory function in 50% of cases; this residual pulmonary abnormality is present even after antifungal treatment. To date, there is no effective treatment for PF. However, the use of antifungal drugs in combination with other antibiotics or immunomodulatory compounds, as well as biological therapies that include a monoclonal antibody specific to neutrophils, or prophylactic vaccination employing a recombinant antigen of Paracoccidioides brasiliensis that successfully attenuated PF, has been reported. Additionally, mesenchymal stem cell transplantation in combination with antifungal therapy slightly reduced the inflammatory response and profibrotic molecules induced by P. brasiliensis infection. In this review, I report experimental findings from several studies aiming to identify promising therapeutic strategies for treating PF developed in PCM. View Full-Text
Keywords: Paracoccidioides spp.; paracoccidioidomycosis; pulmonary fibrosis; therapy; treatment; itraconazole Paracoccidioides spp.; paracoccidioidomycosis; pulmonary fibrosis; therapy; treatment; itraconazole
Show Figures

Figure 1

MDPI and ACS Style

González, Á. The Therapy of Pulmonary Fibrosis in Paracoccidioidomycosis: What Are the New Experimental Approaches? J. Fungi 2020, 6, 217.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop